NRSN NeuroSense Therapeutics Ltd. Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1875091 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-9.0%
TTM EPS YoY18.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-2,175.0%
ROA-397.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets251.8%
Debt / equity—
Current ratio0.31x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.69x
Accruals ratio-123.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $6.23M | $5.70M |
| SG&A expense | $4.86M | $4.20M |
| Operating income | -$11.09M | -$9.90M |
| Net income | -$11.12M | -$10.21M |
| EBITDA | -$11.07M | -$9.88M |
| EPS (basic) | -0.44 | -0.54 |
| EPS (diluted) | -0.44 | -0.54 |
| Weighted avg. shares (diluted) | 25.48M | 18.60M |
| Balance sheet | ||
| Cash & equivalents | $166,000 | $3.38M |
| Current assets | $778,000 | $4.40M |
| PP&E, net | $58,000 | $66,000 |
| Total assets | $1.03M | $4.58M |
| Current liabilities | $2.52M | $1.99M |
| Total liabilities | $2.59M | $1.99M |
| Shareholders' equity | -$1.56M | $2.58M |
| Shares outstanding | 32.56M | 23.23M |
| Cash flow statement | ||
| Operating cash flow | -$7.67M | -$10.13M |
| Capital expenditure | $8,000 | $3,000 |
| Free cash flow | -$7.68M | -$10.14M |
| Investing cash flow | -$8,000 | $1,000 |
| Financing cash flow | $4.43M | $10.91M |
| Depreciation & amortization | $16,000 | $22,000 |
| Stock-based compensation | $2.14M | $557,000 |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.